SARS-CoV-2 Mutation Detail Information

Virus Mutation SARS-CoV-2 Mutation N450K


Basic Characteristics of Mutations
Mutation Site N450K
Mutation Site Sentence Mutating N450K is predicted by FoldX to destabilize the spike protein by more than 0.8 kcal/mol, which is considered destabilizing, for both the closed and open/ACE2-bound conformation (FoldX DeltaDeltaG), while not affecting the interaction energy with ACE2 (FoldX Interaction DeltaDeltaG).
Mutation Level Amino acid level
Mutation Type Nonsynonymous substitution
Gene/Protein/Region S
Standardized Encoding Gene S  
Genotype/Subtype B.1.214.2
Viral Reference MN908947
Functional Impact and Mechanisms
Disease COVID-19    
Immune Y
Target Gene -
Clinical and Epidemiological Correlations
Clinical Information -
Treatment -
Location Belgium
Literature Information
PMID 39390446
Title Emergence of the B.1.214.2 SARS-CoV-2 lineage with an Omicron-like spike insertion and a unique upper airway immune signature
Author Holtz A,Van Weyenbergh J,Hong SL,Cuypers L,O'Toole A,Dudas G,Gerdol M,Potter BI,Ntoumi F,Mapanguy CCM,Vanmechelen B,Wawina-Bokalanga T,Van Holm B,Menezes SM,Soubotko K,Van Pottelbergh G,Wollants E,Vermeersch P,Jacob AS,Maes B,Obbels D,Matheeussen V,Martens G,Gras J,Verhasselt B,Laffut W,Vael C,Goegebuer T,van der Kant R,Rousseau F,Schymkowitz J,Serrano L,Delgado J,Wenseleers T,Bours V,Andre E,Suchard MA,Rambaut A,Dellicour S,Maes P,Durkin K,Baele G
Journal BMC infectious diseases
Journal Info 2024 Oct 10;24(1):1139
Abstract We investigate the emergence, mutation profile, and dissemination of SARS-CoV-2 lineage B.1.214.2, first identified in Belgium in January 2021. This variant, featuring a 3-amino acid insertion in the spike protein similar to the Omicron variant, was speculated to enhance transmissibility or immune evasion. Initially detected in international travelers, it substantially transmitted in Central Africa, Belgium, Switzerland, and France, peaking in April 2021. Our travel-aware phylogeographic analysis, incorporating travel history, estimated the origin to the Republic of the Congo, with primary European entry through France and Belgium, and multiple smaller introductions during the epidemic. We correlate its spread with human travel patterns and air passenger data. Further, upon reviewing national reports of SARS-CoV-2 outbreaks in Belgian nursing homes, we found this strain caused moderately severe outcomes (8.7% case fatality ratio). A distinct nasopharyngeal immune response was observed in elderly patients, characterized by 80% unique signatures, higher B- and T-cell activation, increased type I IFN signaling, and reduced NK, Th17, and complement system activation, compared to similar outbreaks. This unique immune response may explain the variant's epidemiological behavior and underscores the need for nasal vaccine strategies against emerging variants.
Sequence Data -
Mutation Information
Note
Basic Characteristics of Mutations
  • Mutation Site: The specific location in a gene or protein sequence where a change occurs.
  • Mutation Level: The level at which a mutation occurs, including the nucleotide or amino acid level.
  • Mutation Type: The nature of the mutation, such as missense mutation, nonsense mutation, synonymous mutation, etc.
  • Gene/Protein/Region: Refers to the specific region of the virus where the mutation occurs. Including viral genes, viral proteins, or a specific viral genome region. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main
  • Gene/Protein/Region studied in the article is marked.
  • Genotype/Subtype: Refers to the viral genotype or subtype where the mutation occurs. If the article does not specifically indicate the relationship between the mutation and its correspondence, the main Genotype/Subtype studied in the article is marked.
  • Viral Reference: Refers to the standard virus strain used to compare and analyze viral sequences.
Functional Impact and Mechanisms
  • Disease: An abnormal physiological state with specific symptoms and signs caused by viral infection.
  • Immune: The article focuses on the study of mutations and immune.
  • Target Gene: Host genes that viral mutations may affect.
Clinical and Epidemiological Correlations
  • Clinical Information: The study is a clinical or epidemiological study and provides basic information about the population.
  • Treatment: The study mentioned a certain treatment method, such as drug resistance caused by mutations. If the study does not specifically indicate the relationship between mutations and their correspondence treatment, the main treatment studied in the article is marked.
  • Location: The source of the research data.
Literature Information
  • Sequence Data: The study provides the data accession number.